SiBone (SIBN) Competitors

$14.24 -0.43 (-2.91%)

As of 01:09 PM Eastern

SIBN vs. TMDX, LMAT, AXGN, NVCR, and ESTA

Should you buy SiBone stock or one of its competitors? MarketBeat compares SiBone with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SiBone include TransMedics Group (TMDX), LeMaitre Vascular (LMAT), AxoGen (AXGN), NovoCure (NVCR), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry.

How does SiBone compare to TransMedics Group?

SiBone (NASDAQ:SIBN) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

98.1% of SiBone shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 3.9% of SiBone shares are held by insiders. Comparatively, 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$206.22M	3.06	-$18.90M	-$0.39	N/A
TransMedics Group	$635.89M	3.73	$190.29M	$4.40	15.58

SiBone presently has a consensus price target of $23.00, indicating a potential upside of 61.48%. TransMedics Group has a consensus price target of $134.00, indicating a potential upside of 95.47%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

TransMedics Group has a net margin of 27.04% compared to SiBone's net margin of -8.10%. TransMedics Group's return on equity of 22.38% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
TransMedics Group	27.04%	22.38%	8.46%

SiBone has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market.

In the previous week, TransMedics Group had 3 more articles in the media than SiBone. MarketBeat recorded 7 mentions for TransMedics Group and 4 mentions for SiBone. TransMedics Group's average media sentiment score of 0.19 beat SiBone's score of -0.53 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
TransMedics Group	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

TransMedics Group beats SiBone on 14 of the 15 factors compared between the two stocks.

How does SiBone compare to LeMaitre Vascular?

SiBone (NASDAQ:SIBN) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

SiBone currently has a consensus target price of $23.00, indicating a potential upside of 61.48%. LeMaitre Vascular has a consensus target price of $112.60, indicating a potential upside of 17.21%. Given SiBone's higher probable upside, research analysts plainly believe SiBone is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

LeMaitre Vascular has a net margin of 24.35% compared to SiBone's net margin of -8.10%. LeMaitre Vascular's return on equity of 15.36% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
LeMaitre Vascular	24.35%	15.36%	9.78%

98.1% of SiBone shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 3.9% of SiBone shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

LeMaitre Vascular has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$206.22M	3.06	-$18.90M	-$0.39	N/A
LeMaitre Vascular	$249.60M	8.79	$57.73M	$2.71	35.45

In the previous week, SiBone had 1 more articles in the media than LeMaitre Vascular. MarketBeat recorded 4 mentions for SiBone and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.18 beat SiBone's score of -0.53 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
LeMaitre Vascular	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Summary

LeMaitre Vascular beats SiBone on 12 of the 17 factors compared between the two stocks.

How does SiBone compare to AxoGen?

AxoGen (NASDAQ:AXGN) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

80.3% of AxoGen shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Comparatively, 3.9% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.38	-$15.70M	-$0.64	N/A
SiBone	$206.22M	3.06	-$18.90M	-$0.39	N/A

SiBone has a net margin of -8.10% compared to AxoGen's net margin of -13.21%. SiBone's return on equity of -9.56% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
SiBone	-8.10%	-9.56%	-7.06%

AxoGen currently has a consensus price target of $46.50, suggesting a potential upside of 17.03%. SiBone has a consensus price target of $23.00, suggesting a potential upside of 61.48%. Given SiBone's stronger consensus rating and higher probable upside, analysts clearly believe SiBone is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

AxoGen has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

In the previous week, AxoGen and AxoGen both had 4 articles in the media. AxoGen's average media sentiment score of 1.03 beat SiBone's score of -0.53 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

SiBone beats AxoGen on 8 of the 15 factors compared between the two stocks.

How does SiBone compare to NovoCure?

SiBone (NASDAQ:SIBN) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

SiBone has a net margin of -8.10% compared to NovoCure's net margin of -25.66%. SiBone's return on equity of -9.56% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
NovoCure	-25.66%	-50.82%	-16.48%

In the previous week, SiBone had 4 more articles in the media than NovoCure. MarketBeat recorded 4 mentions for SiBone and 0 mentions for NovoCure. NovoCure's average media sentiment score of 0.09 beat SiBone's score of -0.53 indicating that NovoCure is being referred to more favorably in the news media.

Company	Overall Sentiment
SiBone	Negative
NovoCure	Neutral

SiBone currently has a consensus price target of $23.00, suggesting a potential upside of 61.48%. NovoCure has a consensus price target of $27.29, suggesting a potential upside of 58.62%. Given SiBone's stronger consensus rating and higher possible upside, equities research analysts clearly believe SiBone is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

SiBone has higher earnings, but lower revenue than NovoCure. SiBone is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$206.22M	3.06	-$18.90M	-$0.39	N/A
NovoCure	$674.41M	2.95	-$136.23M	-$1.53	N/A

98.1% of SiBone shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 3.9% of SiBone shares are held by insiders. Comparatively, 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

SiBone beats NovoCure on 11 of the 16 factors compared between the two stocks.

How does SiBone compare to Establishment Labs?

SiBone (NASDAQ:SIBN) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

SiBone has a net margin of -8.10% compared to Establishment Labs' net margin of -19.05%. SiBone's return on equity of -9.56% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Establishment Labs	-19.05%	-218.77%	-12.31%

SiBone has higher earnings, but lower revenue than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$206.22M	3.06	-$18.90M	-$0.39	N/A
Establishment Labs	$229.58M	9.23	-$51.06M	-$1.49	N/A

In the previous week, SiBone had 1 more articles in the media than Establishment Labs. MarketBeat recorded 4 mentions for SiBone and 3 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.74 beat SiBone's score of -0.53 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Establishment Labs	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

98.1% of SiBone shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 3.9% of SiBone shares are owned by insiders. Comparatively, 10.0% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

SiBone presently has a consensus price target of $23.00, indicating a potential upside of 61.48%. Establishment Labs has a consensus price target of $87.14, indicating a potential upside of 21.02%. Given SiBone's stronger consensus rating and higher possible upside, analysts clearly believe SiBone is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

SiBone beats Establishment Labs on 10 of the 15 factors compared between the two stocks.

Get SiBone News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SIBN vs. The Competition

Export

Metric	SiBone	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$631.35M	$6.86B	$6.39B	$12.47B
Dividend Yield	N/A	1.69%	2.76%	5.27%
P/E Ratio	-36.50	46.71	20.84	25.88
Price / Sales	3.06	73.23	514.47	69.69
Price / Cash	N/A	24.91	43.49	56.67
Price / Book	3.53	6.64	10.44	7.15
Net Income	-$18.90M	$158.10M	$3.57B	$337.22M
7 Day Performance	-3.89%	2.00%	3.02%	3.40%
1 Month Performance	8.31%	1.94%	2.47%	3.51%
1 Year Performance	-23.38%	-1.04%	36.43%	36.52%

SiBone Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SIBN SiBone	2.3908 of 5 stars	$14.24 -2.9%	$23.00 +61.5%	-20.2%	$631.35M	$206.22M	N/A	350
TMDX TransMedics Group	4.4254 of 5 stars	$67.71 -0.9%	$135.00 +99.4%	-43.3%	$2.34B	$605.49M	15.38	210	Analyst Forecast
LMAT LeMaitre Vascular	4.8112 of 5 stars	$101.40 +0.6%	$112.60 +11.0%	+21.3%	$2.32B	$256.28M	37.49	490	Positive News
AXGN AxoGen	3.2567 of 5 stars	$42.73 +1.9%	$46.50 +8.8%	+274.4%	$2.27B	$225.21M	N/A	450	Positive News
NVCR NovoCure	3.3914 of 5 stars	$17.39 -0.4%	$27.29 +56.9%	-1.5%	$2.01B	$655.35M	N/A	1,605

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SIBN) was last updated on 5/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SiBone (SIBN) Competitors

SIBN vs. TMDX, LMAT, AXGN, NVCR, and ESTA

How does SiBone compare to TransMedics Group?

Summary

How does SiBone compare to LeMaitre Vascular?

Summary

How does SiBone compare to AxoGen?

Summary

How does SiBone compare to NovoCure?

Summary

How does SiBone compare to Establishment Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SiBone (SIBN) Competitors

SIBN vs. TMDX, LMAT, AXGN, NVCR, and ESTA

How does SiBone compare to TransMedics Group?

Do institutionals and insiders have more ownership in SIBN or TMDX?

Which has stronger earnings & valuation, SIBN or TMDX?

Do analysts prefer SIBN or TMDX?

Is SIBN or TMDX more profitable?

Which has more volatility & risk, SIBN or TMDX?

Does the media prefer SIBN or TMDX?

Summary

How does SiBone compare to LeMaitre Vascular?

Do analysts recommend SIBN or LMAT?

Is SIBN or LMAT more profitable?

Do insiders and institutionals have more ownership in SIBN or LMAT?

Which has better earnings & valuation, SIBN or LMAT?

Does the media favor SIBN or LMAT?

Which has more volatility and risk, SIBN or LMAT?

Summary

How does SiBone compare to AxoGen?

Do insiders & institutionals believe in AXGN or SIBN?

Which has stronger earnings and valuation, AXGN or SIBN?

Is AXGN or SIBN more profitable?

Do analysts rate AXGN or SIBN?

Which has more volatility and risk, AXGN or SIBN?

Does the media refer more to AXGN or SIBN?

Summary

How does SiBone compare to NovoCure?

Is SIBN or NVCR more profitable?

Does the media refer more to SIBN or NVCR?

Do analysts rate SIBN or NVCR?

Which has more risk and volatility, SIBN or NVCR?

Which has higher earnings & valuation, SIBN or NVCR?

Do insiders & institutionals believe in SIBN or NVCR?

Summary

How does SiBone compare to Establishment Labs?

Is SIBN or ESTA more profitable?

Which has stronger earnings & valuation, SIBN or ESTA?

Does the media prefer SIBN or ESTA?

Do insiders and institutionals have more ownership in SIBN or ESTA?

Which has more risk & volatility, SIBN or ESTA?

Do analysts rate SIBN or ESTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools